ylliX - Online Advertising Network
Press Release

ZEN Graphene Solutions Announces Exclusive Worldwide Rights to Commercialize Rapid, Saliva-Based COVID-19 Antigen Testing Technology

ZEN Graphene Solutions Announces Exclusive Worldwide Rights to Commercialize Rapid, Saliva-Based COVID-19 Antigen Testing Technology

<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>

GUELPH, ON / ACCESSWIRE / June 17, 2021 / ZEN Graphene Solutions Ltd. (“ZEN” or the “Company”) (TSXV:ZEN)(OTC PINK:ZENYF), a Canadian, next-gen nanomaterials technology company, is pleased to announce that it has signed an exclusive agreement with McMaster University to be the global commercializing partner for a newly developed aptamer-based, SARS-CoV-2 rapid detection technology, developed by a team of researchers under the guidance of Drs.

...read full article on Accesswire

ylliX - Online Advertising Network